Min-Han Tan: Cancer patients deserve the most informed treatment options
Min-Han Tan, CEO and Medical Director at Lucence, shared the post on LinkedIn:
“Cancer patients deserve the most informed treatment options.
Combining circulating tumor DNA and RNA in a single blood test uncovers more FDA-actionable biomarkers for treating cancer patients than ctDNA-alone testing.
I am profoundly grateful to CMS and MolDx for their expanded Medicare coverage decision for LiquidHALLMARK ctDNA/ctRNA.
This recognition of clinical utility means more U.S. cancer patients will now have access to ctDNA and RNA liquid biopsies, providing them with the information they need to guide FDA-approved treatment options.
Today, we are honored to be the first to offer a fully Medicare-covered ctDNA and ctRNA liquid biopsy – a meaningful step forward in expanding precision medicine to more patients.
This could not have happened without the trust and support of physicians, patients, partners, and the incredible Lucence team over the last 8 years who made this milestone possible for cancer patients.
To each of you who believed in this mission – thank you from the bottom of my heart!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023